Literature DB >> 19199878

The perils of Alzheimer's drug development.

Lon S Schneider1, Debomoy K Lahiri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19199878      PMCID： PMC2747724          DOI： 10.2174/156720509787313871

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN： 1567-2050            Impact factor:   3.498


× No keyword cloud information.
  8 in total

Review 1.  Metrifonate for Alzheimer's disease.

Authors:  J M López-Arrieta; L Schneider
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 2.  Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

3.  Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

Authors:  M E Risner; A M Saunders; J F B Altman; G C Ormandy; S Craft; I M Foley; M E Zvartau-Hind; D A Hosford; A D Roses
Journal:  Pharmacogenomics J       Date:  2006-01-31       Impact factor: 3.550

4.  Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.

Authors:  M R Farlow; D K Lahiri; J Poirier; J Davignon; L Schneider; S L Hui
Journal:  Neurology       Date:  1998-03       Impact factor: 9.910

Review 5.  Barriers to Alzheimer disease drug discovery and development in the biotechnology industry.

Authors:  L D Altstiel
Journal:  Alzheimer Dis Assoc Disord       Date:  2002       Impact factor: 2.703

Review 6.  Prevention therapeutics of dementia.

Authors:  Lon S Schneider
Journal:  Alzheimers Dement       Date:  2007-12-21       Impact factor: 21.566

7.  Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease.

Authors:  Ahmadul Kadir; Niels Andreasen; Ove Almkvist; Anders Wall; Anton Forsberg; Henry Engler; Göran Hagman; Marie Lärksäter; Bengt Winblad; Henrik Zetterberg; Kaj Blennow; Bengt Långström; Agneta Nordberg
Journal:  Ann Neurol       Date:  2008-05       Impact factor: 10.422

8.  Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.

Authors:  J Poirier; M C Delisle; R Quirion; I Aubert; M Farlow; D Lahiri; S Hui; P Bertrand; J Nalbantoglu; B M Gilfix; S Gauthier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205
  8 in total
  16 in total

Review 1.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

2.  Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease.

Authors:  Scott E Counts; Balmiki Ray; Elliott J Mufson; Sylvia E Perez; Bin He; Debomoy K Lahiri
Journal:  J Clin Immunol       Date:  2014-04-24       Impact factor: 8.317

3.  Increasing the success rate for Alzheimer's disease drug discovery and development.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Expert Opin Drug Discov       Date:  2012-03-23       Impact factor: 6.098

Review 4.  Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders.

Authors:  Justin M Long; Debomoy K Lahiri
Journal:  Exp Neurol       Date:  2012-01-05       Impact factor: 5.330

5.  Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?

Authors:  Robert E Becker; Nigel H Greig
Journal:  Alzheimers Dement       Date:  2012-03-30       Impact factor: 21.566

Review 6.  Why so few drugs for Alzheimer's disease? Are methods failing drugs?

Authors:  R E Becker; N H Greig
Journal:  Curr Alzheimer Res       Date:  2010-11       Impact factor: 3.498

7.  Phenserine efficacy in Alzheimer's disease.

Authors:  Bengt Winblad; Ezio Giacobini; Lutz Frölich; Lawrence T Friedhoff; Gosse Bruinsma; Robert E Becker; Nigel H Greig
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 8.  Targeting Abeta and tau in Alzheimer's disease, an early interim report.

Authors:  Todd E Golde; Leonard Petrucelli; Jada Lewis
Journal:  Exp Neurol       Date:  2009-08-27       Impact factor: 5.330

9.  Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype.

Authors:  Marilyn Albert; Anja Soldan; Rebecca Gottesman; Guy McKhann; Ned Sacktor; Leonie Farrington; Maura Grega; Raymond Turner; Yi Lu; Shanshan Li; Mei-Cheng Wang; Ola Selnes
Journal:  Curr Alzheimer Res       Date:  2014       Impact factor: 3.498

10.  A Combination of Essential Fatty Acids, Panax Ginseng Extract, and Green Tea Catechins Modifies Brain fMRI Signals in Healthy Older Adults.

Authors:  O T Carmichael; S Pillai; P Shankapal; A McLellan; D G Kay; B T Gold; J N Keller
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.